New Clinical Trial: Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas (NCT03478462)
WHY IT MATTERS
This trial offers a potential treatment option for children with relapsed or refractory neuroblastoma, sarcomas, and other pediatric solid tumors where standard treatments have failed—conditions with very limited curative options.
Researchers are testing a new cancer drug called CLR 131 in children and young adults whose cancers have come back or stopped responding to standard treatments. The study includes kids with several types of hard-to-treat cancers like neuroblastoma, sarcomas, and brain tumors. This is an early-stage study to figure out the right dose and see if the drug is safe and effective.
NCT ID: NCT03478462 Status: ACTIVE_NOT_RECRUITING Conditions: Pediatric Solid Tumor, Pediatric Lymphoma, Pediatric Brain Tumor, DIPG, Neuroblastoma, Ewing Sarcoma, Rhabdomyosarcoma, Osteosarcoma Phase: PHASE1 Enrollment: 30 Sponsor: Cellectar Biosciences, Inc. Summary: The study evaluates CLR 131 in children, adolescents, and young adults with relapsed or refractory malignant solid tumors and lymphoma and recurrent or refractory malignant brain tumors for which there are no standard treatment options with curative potential.
ASK YOUR DOCTOR
If your child has relapsed or refractory neuroblastoma, sarcoma, or another eligible pediatric cancer, ask your oncologist whether CLR 131 trial eligibility should be discussed, though the trial is currently not recruiting new patients.